Fulcrum Therapeutics Inc (NAS:FULC)
$ 7.47 -0.03 (-0.4%) Market Cap: 464.29 Mil Enterprise Value: 238.89 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 48/100

Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 10:35PM GMT
Release Date Price: $6.45 (+14.97%)
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

All right. Welcome, everyone, to this session of the Crédit Suisse Healthcare Conference. I'm Judah Frommer, Smid-cap Biotech Analyst here at Crédit Suisse. And we're very excited to have Bryan Stuart, CEO of Fulcrum Therapeutics with us. Bryan, maybe we'll just jump in with an intro to the company, specifically some background on the FulcrumSeek platform that I think investors forget kind of drives the discovery process here.

Bryan E. Stuart
Fulcrum Therapeutics, Inc. - President, CEO & Director

Yes, absolutely. And thanks, everyone, for joining us. So Fulcrum was started about 6 or 7 years ago, really around the idea of identifying targets to modulate gene expression in order to come up with disease-modifying therapies for genetically defined rare diseases. So the whole idea is start with genetically defined rare disease, known root cause and look for a target that were either up or downregulate gene expression and be able to come up with a drug that is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot